125 related articles for article (PubMed ID: 38875893)
1. In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies.
Amadesi S; Amedeo A; Rinaldi M; Palombo M; Giannella M; Gaibani P
Diagn Microbiol Infect Dis; 2024 May; 110(1):116372. PubMed ID: 38875893
[TBL] [Abstract][Full Text] [Related]
2. Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain.
Castillo-Polo JA; Hernández-García M; Morosini MI; Pérez-Viso B; Soriano C; De Pablo R; Cantón R; Ruiz-Garbajosa P
J Antimicrob Chemother; 2023 May; 78(5):1259-1264. PubMed ID: 36964710
[TBL] [Abstract][Full Text] [Related]
3. Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-
Castillo-Polo JA; Hernández-García M; Maruri-Aransolo A; de la Vega C; Ruiz-Garbajosa P; Cantón R
Microbiol Spectr; 2024 Apr; 12(4):e0277623. PubMed ID: 38415657
[TBL] [Abstract][Full Text] [Related]
4. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
Zhang P; Hu H; Shi Q; Sun L; Wu X; Hua X; McNally A; Jiang Y; Yu Y; Du X
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0127922. PubMed ID: 36794957
[TBL] [Abstract][Full Text] [Related]
5.
Wang C; Zhao J; Liu Z; Sun A; Sun L; Li B; Lu B; Liu Y; Cao B
Front Microbiol; 2021; 12():727946. PubMed ID: 34630354
[TBL] [Abstract][Full Text] [Related]
6. Concomitant Resistance to Cefiderocol and Ceftazidime/Avibactam in Two Carbapenemase-Producing
Bellinzona G; Merla C; Corbella M; Iskandar EN; Seminari E; Di Matteo A; Gaiarsa S; Petazzoni G; Sassera D; Baldanti F; Piazza A; Cambieri P
Microb Drug Resist; 2024 Jan; 30(1):21-26. PubMed ID: 37870558
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
[TBL] [Abstract][Full Text] [Related]
8. Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based β-lactamase inhibitor combinations and cefiderocol.
Di Pilato V; Codda G; Niccolai C; Willison E; Wong JLC; Coppo E; Frankel G; Marchese A; Rossolini GM
Int J Antimicrob Agents; 2024 Jan; 63(1):107030. PubMed ID: 37931849
[TBL] [Abstract][Full Text] [Related]
9. KPC-2 allelic variants in
Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
[TBL] [Abstract][Full Text] [Related]
10. Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.
Nicola F; Cejas D; González-Espinosa F; Relloso S; Herrera F; Bonvehí P; Smayevsky J; Figueroa-Espinosa R; Gutkind G; Radice M
Microbiol Spectr; 2022 Dec; 10(6):e0373322. PubMed ID: 36445147
[TBL] [Abstract][Full Text] [Related]
11. Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.
Shen S; Tang C; Ding L; Han R; Yin D; Yang W; Guo Y; Hu F
mSphere; 2022 Dec; 7(6):e0048722. PubMed ID: 36374086
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512
Tiseo G; Falcone M; Leonildi A; Giordano C; Barnini S; Arcari G; Carattoli A; Menichetti F
Open Forum Infect Dis; 2021 Jun; 8(6):ofab141. PubMed ID: 34189161
[TBL] [Abstract][Full Text] [Related]
14. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.
Poirel L; Sadek M; Kusaksizoglu A; Nordmann P
Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):677-680. PubMed ID: 35088164
[TBL] [Abstract][Full Text] [Related]
15. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
[TBL] [Abstract][Full Text] [Related]
16. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
Zheng M; Li FH; Liu J; Li WJ; Yin RX; Cai DT; Andrey DO; Zheng SL; Gales AC; Zhang WJ; Sun J; Liao XP; Yu Y
J Antimicrob Chemother; 2024 May; 79(5):1069-1080. PubMed ID: 38526879
[TBL] [Abstract][Full Text] [Related]
18. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
[TBL] [Abstract][Full Text] [Related]
19. Meropenem/vaborbactam activity
Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
[TBL] [Abstract][Full Text] [Related]
20. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
